Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05217667 · ClinicalTrials.gov registry record · Phase 2

Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)

A Phase 2 study of Homozygous Familial Hypercholesterolemia, sponsored by Arrowhead Pharmaceuticals.

Active
Registry status
Phase 2
Development phase
18
Enrollment target
7
Study locations

NCT05217667 is a Phase 2 study of Homozygous Familial Hypercholesterolemia that is active but no longer recruiting, run by Arrowhead Pharmaceuticals. The registered enrollment target is 18 participants, below the 249-participant average among 6 other Homozygous Familial Hypercholesterolemia trials with a reported enrollment target (93% lower). The trial reports 7 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05217667, a Phase 2 study of Homozygous Familial Hypercholesterolemia, is active but no longer recruiting, sponsored by Arrowhead Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
18 participants
Enrollment target
7
Study locations

Study Summary

Participants with documented homozygous familial hypercholesterolemia (HoFH) who have provided informed consent will receive 2 open-label doses of ARO-ANG3 and be evaluated for safety and efficacy parameters through 36 weeks. Participants who complete the first 36 week treatment period may opt to continue in an additional 24-month extension period during which they will receive up to 8 doses open-label doses of ARO-ANG3.

Conditions Studied

Homozygous Familial Hypercholesterolemia

Interventions

  • DRUG ARO-ANG 3 Injection

Study Locations (7)

Quebec

  • Research Site 2 - Chicoutimi
  • Research Site 1 - Québec

New York

  • Research Site 4 - Mount Sinai

Ohio

  • Research Site 5 - Cincinnati

New South Wales

  • Research Site 8 - Camperdown

Western Australia

  • Research Site 3 - Nedlands

Other

  • Research Site 7 - Johannesburg

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2022-04-22
Est. Completion 2025-11
Phase Phase 2

Sponsor

Arrowhead Pharmaceuticals

15 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05217667

The ClinicalTrials.gov registry entry for NCT05217667 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 249-participant average among 6 other Homozygous Familial Hypercholesterolemia trials with a reported enrollment target (93% lower). The listed sponsor is Arrowhead Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Homozygous Familial Hypercholesterolemia appearing as the primary indexed condition, and to 1 intervention - of which ARO-ANG 3 Injection is the first listed.

NCT05217667 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Quebec, New York, Ohio.

Frequently Asked Questions

What is clinical trial NCT05217667 about?

NCT05217667 is a clinical study titled "Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)". Participants with documented homozygous familial hypercholesterolemia (HoFH) who have provided informed consent will receive 2 open-label doses of ARO-ANG3 and be evaluated for safety and efficacy parameters through 36 weeks. Participants who complete the first 36 week treatment period may opt to co...

What is the current status of trial NCT05217667?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2022-04-22. Estimated completion is 2025-11.

What conditions does trial NCT05217667 study?

This clinical trial studies the following conditions: Homozygous Familial Hypercholesterolemia.

What interventions are being tested in trial NCT05217667?

The interventions under investigation include: ARO-ANG 3 Injection (DRUG).

Who is sponsoring clinical trial NCT05217667?

This trial is sponsored by Arrowhead Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05217667 being conducted?

This trial has 7 study locations across New York, Ohio, New South Wales, Western Australia, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Homozygous Familial Hypercholesterolemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Homozygous Familial Hypercholesterolemia

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.